Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
O -methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O -position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to...
Saved in:
| Published in | Cancer research (Chicago, Ill.) Vol. 79; no. 17; pp. 4331 - 4338 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.09.2019
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | O
-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O
-position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches that could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. Temozolomide, unlike other alkylators, activated the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. Temozolomide induced growth delay, DNA double-strand breaks, and G
-M cell-cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with temozolomide increased sensitivity to ATR inhibitors both
and
across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and temozolomide. As ATR inhibitors are currently being tested in clinical trials, and temozolomide is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. SIGNIFICANCE: Monofunctional alkylating agents sensitize MGMT-deficient tumor cells to ATR inhibitors. |
|---|---|
| AbstractList | O
-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O
-position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches that could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. Temozolomide, unlike other alkylators, activated the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. Temozolomide induced growth delay, DNA double-strand breaks, and G
-M cell-cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with temozolomide increased sensitivity to ATR inhibitors both
and
across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and temozolomide. As ATR inhibitors are currently being tested in clinical trials, and temozolomide is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. SIGNIFICANCE: Monofunctional alkylating agents sensitize MGMT-deficient tumor cells to ATR inhibitors. O6-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O6-position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches that could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. Temozolomide, unlike other alkylators, activated the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. Temozolomide induced growth delay, DNA double-strand breaks, and G2-M cell-cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with temozolomide increased sensitivity to ATR inhibitors both in vitro and in vivo across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and temozolomide. As ATR inhibitors are currently being tested in clinical trials, and temozolomide is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. SIGNIFICANCE: Monofunctional alkylating agents sensitize MGMT-deficient tumor cells to ATR inhibitors.O6-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O6-position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches that could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. Temozolomide, unlike other alkylators, activated the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. Temozolomide induced growth delay, DNA double-strand breaks, and G2-M cell-cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with temozolomide increased sensitivity to ATR inhibitors both in vitro and in vivo across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and temozolomide. As ATR inhibitors are currently being tested in clinical trials, and temozolomide is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. SIGNIFICANCE: Monofunctional alkylating agents sensitize MGMT-deficient tumor cells to ATR inhibitors. O 6 -methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O 6 -position of guanine in DNA. MGMT expression is reduced or absent in many tumor types derived from a diverse range of tissues, most notably in glioma. Low MGMT expression confers significant sensitivity to DNA alkylating agents such as temozolomide (TMZ), providing a natural therapeutic index over normal tissue. In this study, we sought to identify novel approaches which could maximally exploit the therapeutic index between tumor cells and normal tissues based on MGMT expression, as a means to enhance selective tumor cell killing. TMZ, unlike other alkylators, activated the Ataxia Telangiectasia and Rad3-related (ATR)-Checkpoint Kinase 1 (Chk1) axis in a manner that was highly dependent on MGMT status. TMZ induced growth delay, DNA double-strand breaks, and G2/M cell cycle arrest, which led to ATR-dependent phosphorylation of Chk1; this effect was dependent on reduced MGMT expression. Treatment of MGMT-deficient cells with TMZ increased sensitivity to ATR inhibitors both in vitro and in vivo across numerous tumor cell types. Taken together, this study reveals a novel approach for selectively targeting MGMT-deficient cells with ATR inhibitors and TMZ. As ATR inhibitors are currently being tested in clinical trials, and TMZ is a commonly used chemotherapeutic, this approach is clinically actionable. Furthermore, this interaction potently exploits a DNA-repair defect found in many cancers. |
| Author | Jackson, Christopher B. Breslin, Hank Sundaram, Ranjini K. Jia, Lanqi Burgenske, Danielle M. Gilad, Oren Sarkaria, Jann N. Bindra, Ranjit S. Kalathil, Aravind N. Noorbakhsh, Seth I. Ganesa, Sachita |
| AuthorAffiliation | 1 Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06511 3 Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905 4 Department of Pathology, Yale University School of Medicine, New Haven, CT 06511 2 Atrin Pharmaceutical, Doylestown, PA 18902 |
| AuthorAffiliation_xml | – name: 4 Department of Pathology, Yale University School of Medicine, New Haven, CT 06511 – name: 3 Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905 – name: 1 Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06511 – name: 2 Atrin Pharmaceutical, Doylestown, PA 18902 |
| Author_xml | – sequence: 1 givenname: Christopher B. surname: Jackson fullname: Jackson, Christopher B. – sequence: 2 givenname: Seth I. orcidid: 0000-0002-3163-2735 surname: Noorbakhsh fullname: Noorbakhsh, Seth I. – sequence: 3 givenname: Ranjini K. surname: Sundaram fullname: Sundaram, Ranjini K. – sequence: 4 givenname: Aravind N. surname: Kalathil fullname: Kalathil, Aravind N. – sequence: 5 givenname: Sachita surname: Ganesa fullname: Ganesa, Sachita – sequence: 6 givenname: Lanqi surname: Jia fullname: Jia, Lanqi – sequence: 7 givenname: Hank surname: Breslin fullname: Breslin, Hank – sequence: 8 givenname: Danielle M. surname: Burgenske fullname: Burgenske, Danielle M. – sequence: 9 givenname: Oren surname: Gilad fullname: Gilad, Oren – sequence: 10 givenname: Jann N. surname: Sarkaria fullname: Sarkaria, Jann N. – sequence: 11 givenname: Ranjit S. surname: Bindra fullname: Bindra, Ranjit S. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31273061$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kVtLwzAUx4NM3EU_gtJHXzpzmqRJEYTR6RxsClqfQy-pi7SNNp3gPr0tu6A--BRC_pdz8huiXmUqhdA54DEAE1cYY-Eyyr1xOHlwQbiEBPQIDYAR4XJKWQ8NDpo-Glr71l4ZYHaC-gQ8TrAPAzSNVGk2pjClzpTzrCqrG71R1lnOlpE7VblOtaoaJ1qXpnZCVRTWaYwziZ6cebXSiW5MbU_RcR4XVp3tzhF6ubuNwnt38Tibh5OFm1KAxg0ShiEAkeIgz3yS-CTPMyZ8n8UkEJylLAkohQRjzhIQIouxLxIc0JxmRBFORuhmm_u-TkqVpe1gdVzI91qXcf0lTazl75dKr-Sr-ZS-aPcOuoDLXUBtPtbKNrLUNm2Xiitl1lZ6HiMeB-CslV787DqU7L-uFVxvBWltrK1VLlPdxI02XbUuJGDZgZIdBNlBkC0oCUJ2oFo3--PeF_zv-wYBIJWy |
| CitedBy_id | crossref_primary_10_1007_s13402_021_00613_0 crossref_primary_10_1158_1535_7163_MCT_21_0305 crossref_primary_10_1016_j_radonc_2021_01_035 crossref_primary_10_1158_1535_7163_MCT_20_0319 crossref_primary_10_18632_oncotarget_28551 crossref_primary_10_12677_WJCR_2022_122006 crossref_primary_10_1016_j_ejmech_2021_113909 crossref_primary_10_1016_j_isci_2020_101450 crossref_primary_10_1093_noajnl_vdab015 crossref_primary_10_1007_s13402_023_00793_x crossref_primary_10_1093_narcan_zcab021 crossref_primary_10_1124_jpet_121_000845 crossref_primary_10_1177_01455613211052338 crossref_primary_10_18632_oncotarget_28090 crossref_primary_10_1097_WCO_0000000000000760 crossref_primary_10_1016_j_semradonc_2021_09_004 crossref_primary_10_3390_cancers14153572 crossref_primary_10_1042_BSR20194127 crossref_primary_10_1002_1878_0261_13020 crossref_primary_10_1038_s41420_021_00654_2 crossref_primary_10_1007_s11912_021_01077_z crossref_primary_10_3390_cancers13143415 crossref_primary_10_1038_s41525_020_0130_7 crossref_primary_10_1038_s41598_021_93775_8 crossref_primary_10_1186_s13046_024_02995_z crossref_primary_10_3390_cancers14071821 crossref_primary_10_1016_j_nec_2020_12_009 crossref_primary_10_1093_neuonc_noae072 crossref_primary_10_1016_j_ctro_2023_100667 crossref_primary_10_1097_PPO_0000000000000540 crossref_primary_10_1016_j_biopha_2022_113659 crossref_primary_10_1126_science_abn7570 crossref_primary_10_3390_cancers14030701 crossref_primary_10_1007_s12035_022_02915_2 crossref_primary_10_1016_j_amc_2020_125555 crossref_primary_10_1080_10408444_2023_2264327 crossref_primary_10_1016_j_bioorg_2021_104942 crossref_primary_10_1093_noajnl_vdad165 crossref_primary_10_1002_ijc_34182 crossref_primary_10_1093_neuonc_noaa106 crossref_primary_10_3390_cancers14235902 crossref_primary_10_3390_cancers16091648 crossref_primary_10_1007_s10904_024_03516_3 crossref_primary_10_1038_s41598_022_09614_x |
| Cites_doi | 10.1038/nrc3185 10.1016/j.molcel.2006.04.023 10.1158/0008-5472.CAN-18-1733 10.1158/1078-0432.CCR-15-0479 10.1021/jacs.6b00162 10.1021/bi9518205 10.1158/1078-0432.CCR-11-2059 10.1056/NEJMoa043331 10.1038/nrm.2017.67 10.1126/scitranslmed.aal2463 10.1038/onc.2014.276 10.1093/bmb/ldm036 10.1016/j.lungcan.2014.08.007 10.1158/0008-5472.CAN-16-2983 10.1007/s11523-015-0397-2 10.1200/JCO.2018.77.7672 |
| ContentType | Journal Article |
| Copyright | 2019 American Association for Cancer Research. |
| Copyright_xml | – notice: 2019 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1158/0008-5472.CAN-18-3394 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7445 |
| EndPage | 4338 |
| ExternalDocumentID | PMC6810597 31273061 10_1158_0008_5472_CAN_18_3394 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA215453 – fundername: NCATS NIH HHS grantid: UL1 TR001863 – fundername: NIGMS NIH HHS grantid: T32 GM007324 |
| GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c411t-9b501918c09fd63b63ffd58665a39875c5b9441b0075b188da068b094f4d3e373 |
| ISSN | 0008-5472 1538-7445 |
| IngestDate | Thu Aug 21 13:53:28 EDT 2025 Mon Jul 21 09:44:48 EDT 2025 Thu Apr 03 06:58:32 EDT 2025 Tue Jul 01 03:59:59 EDT 2025 Thu Apr 24 23:03:46 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| License | 2019 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c411t-9b501918c09fd63b63ffd58665a39875c5b9441b0075b188da068b094f4d3e373 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3163-2735 |
| OpenAccessLink | https://cancerres.aacrjournals.org/content/canres/79/17/4331.full.pdf |
| PMID | 31273061 |
| PQID | 2253271175 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810597 proquest_miscellaneous_2253271175 pubmed_primary_31273061 crossref_citationtrail_10_1158_0008_5472_CAN_18_3394 crossref_primary_10_1158_0008_5472_CAN_18_3394 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-01 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research (Chicago, Ill.) |
| PublicationTitleAlternate | Cancer Res |
| PublicationYear | 2019 |
| References | Thomas (2022061706293861900_bib4) 2017; 77 Verbeek (2022061706293861900_bib1) 2008; 85 Aasland (2022061706293861900_bib14) 2019; 79 Sulkowski (2022061706293861900_bib10) 2017; 9 Avendano (2022061706293861900_bib12) 2015 Pietanza (2022061706293861900_bib18) 2018; 36 Srivenugopal (2022061706293861900_bib2) 1996; 35 Hegi (2022061706293861900_bib3) 2005; 352 Pietanza (2022061706293861900_bib16) 2012; 18 Yoshioka (2022061706293861900_bib7) 2006; 22 Zauderer (2022061706293861900_bib15) 2014; 86 Krajewska (2022061706293861900_bib9) 2015; 34 Fu (2022061706293861900_bib6) 2012; 12 Pietrantonio (2022061706293861900_bib17) 2016; 11 Gupta (2022061706293861900_bib19) 2016; 108 Karnitz (2022061706293861900_bib13) 2015; 21 Saldivar (2022061706293861900_bib8) 2017; 18 Esteller (2022061706293861900_bib5) 1999; 59 Surovtseva (2022061706293861900_bib11) 2016; 138 |
| References_xml | – volume: 12 start-page: 104 year: 2012 ident: 2022061706293861900_bib6 article-title: Balancing repair and tolerance of DNA damage caused by alkylating agents publication-title: Nat Rev Cancer doi: 10.1038/nrc3185 – volume: 22 start-page: 501 year: 2006 ident: 2022061706293861900_bib7 article-title: ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts publication-title: Mol Cell doi: 10.1016/j.molcel.2006.04.023 – volume: 79 start-page: 99 year: 2019 ident: 2022061706293861900_bib14 article-title: Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-kappaB publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-18-1733 – volume: 21 start-page: 4780 year: 2015 ident: 2022061706293861900_bib13 article-title: Molecular pathways: targeting ATR in cancer therapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0479 – volume: 138 start-page: 3844 year: 2016 ident: 2022061706293861900_bib11 article-title: Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay publication-title: J Am Chem Soc doi: 10.1021/jacs.6b00162 – volume: 35 start-page: 1328 year: 1996 ident: 2022061706293861900_bib2 article-title: Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea publication-title: Biochemistry doi: 10.1021/bi9518205 – volume: 59 start-page: 5 year: 1999 ident: 2022061706293861900_bib5 article-title: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia publication-title: Cancer Res – volume: 18 start-page: 1138 year: 2012 ident: 2022061706293861900_bib16 article-title: Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2059 – volume: 352 start-page: 997 year: 2005 ident: 2022061706293861900_bib3 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N Engl J Med doi: 10.1056/NEJMoa043331 – volume: 18 start-page: 622 year: 2017 ident: 2022061706293861900_bib8 article-title: The essential kinase ATR: ensuring faithful duplication of a challenging genome publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm.2017.67 – volume: 9 start-page: 15 year: 2017 ident: 2022061706293861900_bib10 article-title: 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aal2463 – volume: 34 start-page: 3474 year: 2015 ident: 2022061706293861900_bib9 article-title: ATR inhibition preferentially targets homologous recombination-deficient tumor cells publication-title: Oncogene doi: 10.1038/onc.2014.276 – volume: 108 year: 2016 ident: 2022061706293861900_bib19 article-title: Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma publication-title: J Na1tl Cancer Inst – year: 2015 ident: 2022061706293861900_bib12 article-title: Medicinal chemistry of anticancer drugs – volume: 85 start-page: 17 year: 2008 ident: 2022061706293861900_bib1 article-title: O6-methylguanine-DNA methyltransferase inactivation and chemotherapy publication-title: Br Med Bull doi: 10.1093/bmb/ldm036 – volume: 86 start-page: 237 year: 2014 ident: 2022061706293861900_bib15 article-title: Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.08.007 – volume: 77 start-page: 823 year: 2017 ident: 2022061706293861900_bib4 article-title: Temozolomide in the era of precision medicine publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-2983 – volume: 11 start-page: 337 year: 2016 ident: 2022061706293861900_bib17 article-title: Dose-dense temozolomide in patients with MGMT-silenced chemorefractory colorectal cancer publication-title: Target Oncol doi: 10.1007/s11523-015-0397-2 – volume: 36 start-page: 2386 year: 2018 ident: 2022061706293861900_bib18 article-title: Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2018.77.7672 |
| SSID | ssj0005105 |
| Score | 2.5039196 |
| Snippet | O
-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O
-position of guanine in DNA. MGMT expression is reduced or absent... O6-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O6-position of guanine in DNA. MGMT expression is reduced or absent... O 6 -methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes alkyl groups at the O 6 -position of guanine in DNA. MGMT expression is reduced or... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 4331 |
| Title | Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31273061 https://www.proquest.com/docview/2253271175 https://pubmed.ncbi.nlm.nih.gov/PMC6810597 |
| Volume | 79 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLayTqr6Mu2-7CYm7S1yFmPA5jFKt1WrEmldKvUNYTCCjkBFyB7y63dsc8vaaZcXhLgYyd_H8bF9zncQek_DmAtfUmwzRjGMeBTDMBRhEkrFH1syqhKclyvv7NL5cuVejUa7YXZJLabR_s68kv9BFa4BripL9h-Q7RqFC3AO-MIREIbj32EsN-UerNcmiyX89YWKv9rL7WT5ebnGp1KJQ6it_vVuU1aThcxzLecwX1-AWUgzkalKO0PvdKEoUE0aAaBU7_CaUA1tSvJ8Olg4GGTnDxQK-irOq7KsRPg93eqFm2-yTvsVWp1_UhkuXoTFdVZk_XrreZirkEgTPVCFP7IibjaMmtUJ0odfweDSW1TmGM3I1uSa-jEttdjAgLYJXLctu8tNKCTHrsPs6WK-woRjSk2N5AHaNxsNNyXgmc080g90Xfhhe-seug8U1X71-ddeZF75nE2yF3z1w53fPEHHbSuHHs2tacqv0bYD92X9ED1o5h3W3JDoERrJ4jE6XjaRFU_Q6ZBLVs8l65BLluaSpblk1aUFXLJ6Lj1Fl58-rhdnuKmwgSOHkBr7wgXMCI9mfhJ7VHg0SWJXSSCG1IeZbOQKH_xloRxLQTiPw5nHxcx3EiemkjL6DB0VZSFfICuUvuC20NvMjlYRZJ6wY4ewxPMS3x8jp-2lIGrk51UVlDzQ01CXqzAIHqh-DqCfA8ID1c9jNO1euzH6K3964V0LQQCWUm1_hYUsd9sARi5qMyVNO0bPDSRdky2WY8QOwOoeUCrsh3eKLNVq7ErQD2blL3_b5it00v8Zr9FRXe3kG_Bka_FW8-4nli6V9g |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Temozolomide+Sensitizes+MGMT-Deficient+Tumor+Cells+to+ATR+Inhibitors&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Jackson%2C+Christopher+B&rft.au=Noorbakhsh%2C+Seth+I&rft.au=Sundaram%2C+Ranjini+K&rft.au=Kalathil%2C+Aravind+N&rft.date=2019-09-01&rft.eissn=1538-7445&rft.volume=79&rft.issue=17&rft.spage=4331&rft_id=info:doi/10.1158%2F0008-5472.CAN-18-3394&rft_id=info%3Apmid%2F31273061&rft.externalDocID=31273061 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |